4-(3-iodopropyloxy)benzaldehyde | 1165801-51-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-(3-iodopropyloxy)benzaldehyde
• 英文别名: 4-(3-iodopropoxy)benzaldehyde
• CAS: 1165801-51-3
• 化学式: C₁₀H₁₁IO₂
• 分子量: 290.101
• InChiKey: MVWHMRZWXVKZFE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(3-iodopropyloxy)benzaldehyde 在 三乙胺 、 三氟乙酸 、 2,3-二氯-5,6-二氰基-1,4-苯醌 作用下， 以 甲醇 、 乙醚 、 甲苯 为溶剂， 反应 4.25h， 生成 4,4-difluoro-8-[4-((3-iodopropoxy)phenyl)]-4-bora-3a,4a-diazaindacene
  参考文献：
  名称：

  A novel Bodipy-Dipyrrin fluorescent probe: Synthesis and recognition behaviour towards Fe (II) and Zn (II)

  摘要：

  We present the design, synthesis, characterization and spectral studies for a new Zn (II) and Fe (II) selective fluorescent probe, 4,4-Difluoro-8-{3-[(4-phenoxy-dipyrromethene)propoxy]}-4-bora-3a,4a-diazaindacene (DPYBODPY). DPBODPY consists of a terminal fluorophore and a selective ligand and was designed to detect significant changes in absorbance and/or fluorescence on metal ion binding. The fluorophore is based on the Bodipy unit due to its excellent photophysical properties, while the dipyrrin unit has specific recognition abilities for Fe2+ and Zn2+ ions. The combination of these two structures is optimised to achieve significant spectral changes in the presence of Fe2+ and Zn2+ ions. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.dyepig.2012.02.006
• 作为产物：
  描述：

  4-(3-氯丙氧基)苯甲醛 在 sodium iodide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 以99%的产率得到4-(3-iodopropyloxy)benzaldehyde
  参考文献：
  名称：

  A novel Bodipy-Dipyrrin fluorescent probe: Synthesis and recognition behaviour towards Fe (II) and Zn (II)

  摘要：

  We present the design, synthesis, characterization and spectral studies for a new Zn (II) and Fe (II) selective fluorescent probe, 4,4-Difluoro-8-{3-[(4-phenoxy-dipyrromethene)propoxy]}-4-bora-3a,4a-diazaindacene (DPYBODPY). DPBODPY consists of a terminal fluorophore and a selective ligand and was designed to detect significant changes in absorbance and/or fluorescence on metal ion binding. The fluorophore is based on the Bodipy unit due to its excellent photophysical properties, while the dipyrrin unit has specific recognition abilities for Fe2+ and Zn2+ ions. The combination of these two structures is optimised to achieve significant spectral changes in the presence of Fe2+ and Zn2+ ions. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.dyepig.2012.02.006

文献信息

• Tethered indoles as functionalizable ligands for the estrogen receptor
  作者：Bridget G. Trogden、Sung Hoon Kim、Shuyi Lee、John A. Katzenellenbogen

  DOI：10.1016/j.bmcl.2008.11.043

  日期：2009.1

  To create ligands for the estrogen receptor that contain pendant groups for tethering to a poly(amido)amine (PAMAM) dendrimer, we have explored a class of N-substituted 2-phenyl indoles. Attachment of tethers of different length and chemical nature to this non-steroidal indole scaffold gave high affinity ligand-tether conjugates that can be easily functionalized. To further explore the utility of this system, an indole-conjugated dendrimer was prepared and evaluated as an estrogen receptor ligand. (C) 2008 Elsevier Ltd. All rights reserved.
• [EN] NOVEL ANTAGONISTS OF THE GLUCAGON RECEPTOR<br/>[FR] NOUVEAUX ANTAGONISTES DU RÉCEPTEUR AU GLUCAGON
  申请人：METABASIS THERAPEUTICS INC

  公开号：WO2008098244A1

  公开（公告）日：2008-08-14

  [EN] The present invention provides for novel compounds of Formula (I) and pharmaceutically acceptable salts and co-crystals thereof which have glucagon receptor antagonist or inverse agonist activity. The present invention further provides for pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistence and hyperglycemia. The present invention also provides for processes of making the compounds of Formula I, including salts and co-crystals thereof, and pharmaceutical compositions comprising the same.
  [FR] La présente invention propose de nouveaux composés de formule (I) et les sels et co-cristaux pharmaceutiquement acceptables de ceux-ci qui ont une activité antagoniste ou agoniste inverse du récepteur au glucagon. La présente invention propose en outre des compositions pharmaceutiques les comprenant ainsi que des procédés de traitement, de prévention, de retardement de la durée avant la déclaration ou de réduction du risque de développement ou de progression d'une maladie ou d'une condition pour laquelle un ou plusieurs antagonistes du récepteur au glucagon est indiqué, y compris le diabète de type I et II, l'insulinorésistance et l'hyperglycémie. La présente invention propose également des procédés de préparation des composés de formule I, y compris les sels et co-cristaux de ceux-ci, et des compositions pharmaceutiques les comprenant.